NCT03295396 2025-07-28ONC201 in Adults With Recurrent H3 K27M-mutant GliomaJazz PharmaceuticalsPhase 2 Terminated73 enrolled 13 charts 1 FDA
NCT03416530 2025-02-14ONC201 in Pediatric H3 K27M GliomasJazz PharmaceuticalsPhase 1 Terminated134 enrolled 1 FDA
NCT02525692 2024-12-24Oral ONC201 in Adult Recurrent GlioblastomaJazz PharmaceuticalsPhase 2 Terminated84 enrolled 14 charts 1 FDA
NCT03485729 2024-12-24ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerJazz PharmaceuticalsPhase 2 Terminated27 enrolled 11 charts
NCT02863991 2024-07-03Oral ONC201 in Relapsed/Refractory Multiple MyelomaJazz PharmaceuticalsPhase 1/2 Terminated17 enrolled 10 charts